Abstract Details

Title An Ipsilateral Silent Period Study in Relapsing Remitting Multiple Sclerosis during and after Motor Relapse

Topic Clinical Neurophysiology

Presentation(s) S59 - (-)

Poster/Presentation
Number 006

Objective

Background Several studies showed abnormal iSP measures in MS, but data about iSP during and after a motor relapse are not available.

Design/Methods We compared 13 RRMS patients without disability who presented a first upper limb weakness with 19 healthy volunteers. Patients underwent clinical (MRC, NHPT) and neurophysiological examination (MEP latency, iSP onset, amount and duration) at study entry (T1 about one wk after the relapse) and end of the 16th week after a single attack involving for the first time upper arm motor function, unilaterally. iSP measures were obtained from the abductor pollicis brevis of the two sides.

Results MRC and time to complete NHPT in the affected (AA) were worse vs the unaffected (UA) arm and vs controls (p<0.05) at T1 but not at T2, being both measures significantly improved in AA at T2 vs T1 (p<0.05). MS vs controls: delayed iSP onset (AA,UA at T1,T2) p<0.05, lower iSP amount (AA, UA at T1,T2) without significant interhemispheric differences, duration iSP (UA at T1). In MS pts, MEPs had increased latency and lower amplitude in AA and UA vs controls at both times, in AA vs UA at both times, and in the AA at T1 vs AA T2 (p<0.05). At T1, iSP duration in UA inversely correlated with improvement of AA NHPT in T2 (r=-0.54, p=0.05) and not in T1. No correlation with NHPT/MRC of iSP duration in AA and MEPs latency/amplitude in either side.

Conclusions Shortly after a relapse, transient increase of iSP duration over the unaffected limb would indicate impaired efficiency of the affected hemisphere to inhibit the unaffected. This impairment is transient and is related with future recovery outcome.

Authors/Disclosures
Arturo Nuara PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Raffaella Chieffo, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Giancarlo Comi, MD (University Vita-Salute)	Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind.
Letizia M. Leocani, MD (University Vita-Salute San Raffaele, INSPE)	Dr. Leocani has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche . Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Med-ex learning.

��ɫ��

��ɫ��